Evidence map›Paper›PMID 39606233›Full record

ReviewFrontiers in immunology2024

circFOXP1: a potential diagnostic and therapeutic target in human diseases.

Qiang Yi, Xinting Ouyang, Kui Zhong, Zheng Chen, Weijian Zhu, Gangfeng Zhu, Jinghua Zhong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiang Yi *The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Xinting Ouyang *The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Kui Zhong *The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Zheng Chen *The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Weijian ZhuThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Gangfeng ZhuThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Jinghua ZhongDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA (circRNA) are a unique class of non-coding RNAs characterized by their covalently closed loop structures, which grant them properties such as stability and conservation. Among these, circFOXP1 has been implicated in various diseases, including cancers, respiratory, skeletal, and cardiovascular disorders. This review systematically examines circFOXP1's role in disease progression, highlighting its involvement in critical biological processes, including cell proliferation, invasion, apoptosis, and autophagy. Mechanistically, circFOXP1 functions through miRNA sponging, protein interactions, and modulation of key signaling pathways such as Wnt and PI3K/AKT. We discuss its potential as a diagnostic and therapeutic target. Our analysis also identifies key unresolved questions, such as the precise regulatory networks involving circFOXP1 and its translation potential, offering pathways for future research.

Indexed as

Forkhead Transcription FactorsRNA, CircularAnimalsHumansNeoplasmsRepressor ProteinsSignal TransductionForkhead Transcription FactorsFOXP1 protein, humanRepressor ProteinsRNA, CircularbiomarkercircFOXP1circRNAmolecular mechanismstreatment target

Identifiers

PMID39606233
PMCPMC11599189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.